X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with TTK HEALTHCARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs TTK HEALTHCARE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA TTK HEALTHCARE AJANTA PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 25.4 51.5 49.3% View Chart
P/BV x 10.5 9.5 110.3% View Chart
Dividend Yield % 0.6 0.3 187.2%  

Financials

 AJANTA PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
TTK HEALTHCARE
Mar-14
AJANTA PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,720663 259.3%   
Low Rs1,103399 276.4%   
Sales per share (Unadj.) Rs194.6535.6 36.3%  
Earnings per share (Unadj.) Rs45.215.9 283.6%  
Cash flow per share (Unadj.) Rs50.320.0 251.2%  
Dividends per share (Unadj.) Rs8.004.00 200.0%  
Dividend yield (eoy) %0.60.8 75.3%  
Book value per share (Unadj.) Rs132.0137.6 95.9%  
Shares outstanding (eoy) m88.777.77 1,142.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.31.0 731.3%   
Avg P/E ratio x31.233.3 93.7%  
P/CF ratio (eoy) x28.126.5 105.8%  
Price / Book Value ratio x10.73.9 277.0%  
Dividend payout %17.725.1 70.5%   
Avg Mkt Cap Rs m125,2994,127 3,035.8%   
No. of employees `000NA1.7 0.0%   
Total wages/salary Rs m2,570607 423.7%   
Avg. sales/employee Rs ThNM2,436.7-  
Avg. wages/employee Rs ThNM355.2-  
Avg. net profit/employee Rs ThNM72.5-  
INCOME DATA
Net Sales Rs m17,2754,162 415.1%  
Other income Rs m16661 271.7%   
Total revenues Rs m17,4424,223 413.0%   
Gross profit Rs m5,807197 2,946.3%  
Depreciation Rs m45132 1,421.5%   
Interest Rs m4930 163.5%   
Profit before tax Rs m5,474197 2,782.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,46073 2,005.4%   
Profit after tax Rs m4,014124 3,239.8%  
Gross profit margin %33.64.7 709.8%  
Effective tax rate %26.737.0 72.1%   
Net profit margin %23.23.0 780.5%  
BALANCE SHEET DATA
Current assets Rs m7,6391,629 469.0%   
Current liabilities Rs m2,7151,058 256.6%   
Net working cap to sales %28.513.7 207.8%  
Current ratio x2.81.5 182.8%  
Inventory Days Days4330 145.2%  
Debtors Days Days7934 234.2%  
Net fixed assets Rs m6,914556 1,242.8%   
Share capital Rs m17778 227.7%   
"Free" reserves Rs m11,442878 1,302.7%   
Net worth Rs m11,7211,069 1,096.1%   
Long term debt Rs m149159 93.7%   
Total assets Rs m14,8142,399 617.4%  
Interest coverage x112.97.6 1,490.3%   
Debt to equity ratio x00.1 8.5%  
Sales to assets ratio x1.21.7 67.2%   
Return on assets %27.46.4 427.9%  
Return on equity %34.211.6 295.6%  
Return on capital %46.518.5 252.2%  
Exports to sales %55.10.8 6,976.2%   
Imports to sales %6.01.4 428.8%   
Exports (fob) Rs m9,52733 28,957.8%   
Imports (cif) Rs m1,03858 1,779.8%   
Fx inflow Rs m10,42233 31,677.2%   
Fx outflow Rs m1,67863 2,655.8%   
Net fx Rs m8,744-30 -28,866.3%   
CASH FLOW
From Operations Rs m3,264127 2,578.0%  
From Investments Rs m-2,093-146 1,433.5%  
From Financial Activity Rs m-1,18622 -5,414.2%  
Net Cashflow Rs m-153 -592.0%  

Share Holding

Indian Promoters % 73.8 65.4 112.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 3.7 41.9%  
FIIs % 7.6 5.2 146.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 25.8 65.9%  
Shareholders   20,968 12,723 164.8%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  FDC LTD.  SUN PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS